New CEO Szela cuts Aege­ri­on staff again, pulls Jux­tapid out of the EU

Aege­ri­on Phar­ma­ceu­ti­cals CEO Mary Szela is tak­ing out the ax for the sec­ond time in five months, chop­ping off an­oth­er 13% of its staff and pulling its drug Jux­tapid out of the EU and “cer­tain oth­er” un­der­per­form­ing mar­kets.

The lat­est cuts leave the Cam­bridge, MA-based com­pa­ny with about 60% of the staff it start­ed the year with, leav­ing about 120 em­ploy­ees with pink slips.

Aege­ri­on is con­cen­trat­ing its sales ef­forts in the U.S. and key mar­kets like Brazil, look­ing to out-li­cense the drug to part­ners who can make a bet­ter go of it. But it won’t ex­it the EU en­tire­ly, leav­ing be­hind a group to help prep Myalept (me­treleptin for in­jec­tion) for an an­tic­i­pat­ed launch next year. The new move is de­signed to carve out $25 mil­lion to $35 mil­lion in an­nu­al ex­pens­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.